Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers with strong finish in record year 2021
Press release

Siemens Healthineers with strong finish in record year 2021

Siemens Healthineers AG today announced its results for the fourth quarter of fiscal year 2021 that ended September 30, 2021.
Published on November 4, 2021

Fiscal Year 2021 – Outstanding performance in a challenging environment

  • Record revenue of around €18 billion; comparable growth of 19.3% compared to the prior year which was challenged by the COVID-19 pandemic
  • Very good comparable revenue growth of 11.8%, excluding rapid COVID-19 antigen tests; revenue contribution from rapid antigen tests of around €1.1 billion
  • Considerable comparable revenue growth of 11.2% in Imaging, 8.6% in Advanced Therapies, and 42.3% in Diagnostics, excluding rapid antigen tests at 14.7%
  • Excellent start of Varian within Siemens Healthineers; strong revenue contribution of €1.3 billion since the closing of the acquisition on April 15, 2021
  • Adjusted EBIT margin increases by 190 bps to 17.4%
  • Adjusted basic earnings per share up 26% to €2.03
  • Free cash flow reaches record level of around €2.3 billion
  • Proposed dividend of €0.85 per share (corresponding to a 55% pay-out ratio of net income)

Q4 Fiscal Year 2021 – Strong final quarter with peaks in order intake and revenue

  • Very good revenue development also in the fourth quarter – comparable growth of 14.4% from prior-year quarter which was considerably challenged by the COVID-19 pandemic; excluding rapid antigen tests, it was 10.3%
  • Equipment book-to-bill ratio at a very good 1.17
  • Diagnostics revenue with excellent increase of 22.3% year-over-year; excluding the revenue contribution of around €160 million from rapid COVID-19 antigen tests, comparable revenue growth at 7.0%
  • Comparable revenue growth of 11.6% in Imaging; Advanced Therapies grows by 14.5%
  • Continued strong Varian development with equipment book-to-bill ratio of 1.59
  • Adjusted EBIT up to €793 million compared to €631 million in the prior year – margin at 15.3%
  • Adjusted basic earnings per share up 10% to €0.53 from €0.48 in the prior-year quarter

Outlook for Fiscal Year 2022

  • Comparable revenue growth between 0% and 2% expected
  • Excluding revenue from rapid COVID-19 antigen tests, comparable revenue growth between 5% and 7% expected
  • Adjusted basic earnings per share between €2.08 and €2.20

Bernd Montag, CEO of Siemens Healthineers AG:
 »The Siemens Healthineers team successfully ended the record year 2021 with a strong quarter. We demonstrated an agile and prudent response to the pandemic. As a result, we were able to gain further market shares. At the same time, we have introduced significant innovations to the market and adopted an ambitious sustainability program. Together with our colleagues from Varian, we have defined our strategic priorities for the coming years. We start the new fiscal year as an even more holistic and relevant healthcare company with a record order backlog, and we expect to continue our strong business development.«

Download Quarterly Statement(pdf, 380.23 KB)

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.